

15 February 2023

ASX Announcement

Clinical Trial of NovoSorb® SynPath Treatment for Diabetic Foot Ulcers

On 10 August 2022 PolyNovo announced that the first patient had been enrolled in its Randomized Controlled Trial (RCT) evaluating the clinical safety and efficacy of NovoSorb® SynPath for the treatment of chronic diabetic foot ulcers (DFU's).

Chronic wounds advance quickly and, if not treated appropriately may necessitate amputation. SynPath is designed to promote healing by providing a porous network of biodegradable synthetic polymers which act as a template to support the proliferation of vital cells involved in tissue regeneration.

Currently 25 subjects have been enrolled in the trial out of a target 138. We stated in the announcement on 10 August 2022 that we expected enrolment to be completed by April 2023, but now expect this to be early 2H CY23. A review of the first 25 patients is being completed to confirm the study protocol, and we anticipate making an amendment.

Diabetic foot ulcers affect more than 300,000 Americans annually and accounts for more than US\$9 billion in annual expenditures.

Chief Executive Officer, Mr. Swami Raote said *"We are thrilled to invest in this study to assess if NovoSorb SynPath can help patients and clinicians with an alternative which promises better outcomes."*

Chairman, David Williams said *"Many surgeons are already successfully using BTM for the treatment of DFUs, but the time has come for a specific product to treat DFUs and venous leg ulcers. The trial will provide valuable data for surgeons and importantly also for reimbursement."*

This announcement has been authorised by PolyNovo Company Secretary Jan-Marcel Gielen.

Further information:

David Williams
Chairman
Mobile: + 61 414 383 593

Swami Raote
CEO
Mobile: +1 904 314 6346

About PolyNovo®

PolyNovo is a disruptive medical device company, focused on Advanced Wound Care. PolyNovo is an Australian based medical device company that designs, develops, and manufactures dermal regeneration solutions (NovoSorb BTM) using its patented NovoSorb biodegradable polymer technology. Our development program covers Breast Sling, Hernia, and Orthopedic applications. For further information and market presentations see www.polynovo.com

About NovoSorb®

NovoSorb® is a novel range of bio-resorbable polymers that can be produced in many formats including, film, fiber, foam, and coatings. NovoSorb's unique properties provide excellent biocompatibility, control over physical properties, and programmable bio-resorption profile. NovoSorb® BTM is a dermal scaffold for the regeneration of the dermis when lost through extensive surgery or burn.